Sponsor Deadline
Posted: 4/2/2024

Innovative Research in Cancer Nanotechnology (IRCN) (R01 Clinical Trial Not Allowed)

Through this Notice of Funding Opportunity (NOFO) entitled "Innovative Research in Cancer Nanotechnology (IRCN)", the National Cancer Institute (NCI) encourages applications promoting transformative discoveries in cancer biology and/or oncology through the use of nanotechnology. Proposed projects should address overcoming major barriers in cancer biology and/or oncology using nanotechnology and should focus on mechanistic studies to expand the fundamental understanding of nanomaterial and/or nano-device interactions with biological systems. These studies are expected to be relevant to the delivery of nanoparticles and/or nano-devices to desired and intended cancer targets in vivo and/or characterization of detection and diagnostic devices and sensors in vitro. IRCN awards are expected to produce fundamental knowledge to aid future and more informed development of nanotechnology-based cancer interventions. The clinical translation of these interventions is outside of scope of this NOFO.

Application Due Date(s): November 3, 2023; May 3, 2024; Nov 4, 2024; May 5, 2025; Nov 3, 2025; May 4, 2026

PAR-23-246 Expiration Date May 05, 2026

Amount Description

Application budgets are limited to $475K in direct costs per year and need to reflect the actual needs of the proposed project.

The scope of the proposed project should determine the project period. The maximum project period is 5 years.